+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vaccine Contract Manufacturing Market by Business Operations, Type of Expression Systems, Company Size, Scale of Operation, and Geography: Industry Trends and Global Forecasts, 2021-2030

  • PDF Icon

    Report

  • 381 Pages
  • May 2021
  • Region: Global
  • Roots Analysis
  • ID: 5411398

Overview

Taking into consideration prevalent (the COVID-19 pandemic) and anticipated future trends, the global vaccines market is expected to be worth around USD 100 billion by 2025. Recent estimates (as reported in April 2021) suggest that more than 1.06 billion doses have been administered across 172 countries, which roughly translates to 19.7 million doses per day. Although the pandemic is responsible for the current surge in the demand for vaccines, according to the WHO, the current global vaccination rate is nearly 85%. As a result, as the global population grows, the demand for manufacturing vaccines is likely to increase, as well. It is worth highlighting that the vaccine development process is characterized by the need for heavy investments in specialized infrastructure and affiliated expertise, and complex R&D and production protocols. Further, vaccine manufacturing is highly regulated, and due to increasing regulatory stringency, it is gradually becoming difficult for vaccine developers to establish in-house capabilities for the large-scale manufacturing of proprietary vaccine candidates, while ensuing compliance to the evolving standards. As a result, outsourcing vaccine manufacturing operations has become a preferred practice in this segment of the biopharmaceutical industry. The outsourcing-based operating model is common among small and mid-sized innovators, which heavily rely on capable contract manufacturing organizations (CMOs) for clinical- and commercial-scale manufacturing requirements. Over time, several big pharma players, with established in-house capabilities, have also been observed to enter into long-term business relationships with CMOs, in order to optimize internal resource utilization, manage cost of operations, and leverage the niche expertise of specialty service providers.


The contemporary contract services market for vaccines is highly fragmented, featuring a mix of small and mid-sized firms, and established players. Numerous stakeholders presently claim to be actively striving to expand their respective service portfolios; in this context, there has been substantial acquisition activity in this domain, in the recent past. As a result, several of the larger CMOs have developed the required capabilities and expertise to offer end-to-end services, ranging from vaccine development (which includes preliminary R&D, preclinical studies and clinical trials) to regulatory filings, and commercial scale production. It is worth mentioning that to fulfil the growing demand for COVID-19 vaccines and ensure minimal disruption in the supply of these vaccines, several big pharmaceutical companies (such as Bayer, Merck, and Novartis) have offered their manufacturing infrastructure for production of COVID-19 vaccines. Other recent developments in this field include capability expansions, and collaborations focused on expanding geographical presence. In the foreseen future, we expect the demand for core competencies to continue to drive sponsor companies to rely on contract service providers for various aspects of vaccine development and manufacturing. Amidst the tough competition within this domain, the availability of cutting-edge tools and technologies has emerged as a differentiating factor, offering competitive advantage to CMOs that possess them. Given the increased impetus on outsourcing vaccine manufacturing, we anticipate the vaccine contract manufacturing market to grow at a steady pace over the next decade.


Scope Of the Report

The “Vaccine Contract Manufacturing Market (3rd Edition) by Outsourced Business Operations (Cell / Virus Banking, Analytical Testing, Formulation Development, Process Development, Fill / Finish, and Regulatory Filings), Type of Expression Systems (Mammalian, Microbial, and Others), Size of the Company (Small-sized, Mid-sized and Large / Very Large), Scale of Operation (Preclinical / Clinical and Commercial), and Geography (North America (the US), Europe (UK, France, Germany, Italy and Spain), Asia (China, India, Japan and South Korea) and Rest of the World (South Africa): Industry Trends and Global Forecasts” report features an extensive study on contract service providers engaged in the development and manufacturing of vaccines. The study features in-depth analyses, highlighting the capabilities of various vaccine CMOs. 


Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the vaccine contract manufacturing market, featuring a list of active CMOs and an analysis based on a number of relevant parameters, such as year of establishment, size of employee base, location of headquarters, number of vaccine manufacturing facilities, type of service(s) offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), type of expression system used (mammalian, microbial and others) and type of vaccine manufactured (protein vaccine, viral vaccine, DNA vaccine, cancer vaccine, and others).
  • A detailed review of the contract manufacturing landscape for COVID-19 vaccines, featuring a list of service providers and an analysis based on type of service(s) offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings) and geographical location of contract manufacturers (North America, Europe, and Asia-Pacific and Rest of the World), along with competitiveness analysis of companies based in different geographies.
  • A region-wise company competitiveness analysis, highlighting the most prominent vaccine contract manufacturers, based on supplier strength (in terms of experience), and service strength (in terms of service offerings, expression systems used, and scale of operation).
  • Elaborate profiles of the key players based in North America, Europe, and Asia-Pacific having a diverse range of capabilities for development, manufacturing and packaging of vaccines. Each profile includes an overview of the company, its financial performance (if available), information on service portfolio, vaccine manufacturing facilities, recent developments and an informed future outlook. 
  • An analysis of the collaborations that have been established since 2013, based on various parameters, such as year of agreement, type of agreement, scale of operation, type of services mentioned in the deal, type of vaccines manufactured, key therapeutic areas, and location of facility where the project is to be executed. 
  • A detailed analysis of the expansions undertaken (since 2013) by various vaccine contract manufacturing service providers for enhancing their service portfolios, based on a number of parameters, including year of expansion, purpose of expansion (capacity expansion, capability expansion, facility expansion, and new facility), geographical location of facility, scale of operation, type of service(s) offered, highlighting most active players and other details (in terms of new area added to existing facilities, if available).
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired during the time period between 2013-2021, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples (based on revenues), number of employees, and overall experience of the acquired company.
  • A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small, mid-sized, large / very large CMOs) in the market, based on data gathered via secondary and primary research. In addition, the study provides the distribution of global vaccine manufacturing capacity by company size (small, mid-sized, large / very large), geography (North America, Europe and Asia-Pacific), and scale of operation (preclinical / clinical and commercial).
  • An informed estimate of the annual commercial and clinical demand for vaccines (in million liters), which was further segmented as across different types of vaccines, target indications, and geographies.
  • A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry. 
  • A discussion on the potential market drivers, such as the growing vaccines pipeline, increasing outsourcing of vaccine operations and opportunities in the Asia-Pacific region, which are likely to present in the coming years.

One of the key objectives of the report was to estimate the existing market size and future growth opportunities. Based on various parameters, such as growth of the overall vaccine market, cost of goods sold, and direct manufacturing costs, we have provided informed estimates on the evolution of the market for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] type of expression system used (mammalian, microbial, and others), [B] scale of operation (preclinical, clinical, and commercial), [C] company size (small-, mid-sized and large / very large), and [D] key geographical regions (North America (the US), Europe (Italy, Germany, France, Spain, and the UK), and Asia-Pacific (China, India, and Japan), and Rest of the World. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth. 


The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. 


The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Menzo Havenga, CEO, Batavia Biosciences and Claire Otjes, Marketing Manager, Batavia Biosciences
  • Dietmar Katinger, Chief Executive Officer, Polymun Scientific
  • David C Cunningham, Director Corporate Development, Goodwin Biotechnology
  • Ingrid Kromann, Ex-Director – Vaccine Development (currently, the Head of CMC at CEPI)
  • Kevin Daley, Director Pharmaceuticals, Novasep Synthesis
  • Thilo Kamphausen, Director Business Development, Richter-Helm BioLogics
  • Sebastian Schuck, Head of Business Development, Wacker Biotech 
  • Oliver Schub, Senior Business Development Manager, ProBioGen

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.


Key Questions Answered

  • Who are the key players offering vaccine manufacturing services?
  • Which manufacturing services are commonly offered by the vaccine contract manufacturers?
  • Which partnership models are most commonly adopted by stakeholders engaged in this industry?
  • What are the key value drivers of the merger and acquisition activity within this domain?
  • What is the current capacity of vaccine contract manufacturing?
  • What is the annual commercial and clinical demand for vaccines?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to vaccine contract manufacturing?

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines


2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Classification of Vaccines based on Type of Active Ingredient
3.2.1. Live, Attenuated Vaccines
3.2.2. Inactivated Vaccines
3.2.3. Subunit Vaccines
3.2.4. Toxoid Vaccines
3.2.5. DNA Vaccines
3.3. Key Components of Vaccine Formulations
3.4. Vaccine Development and Manufacturing
3.4.1. Identification of Antigen and Manufacturing Process Development
3.4.2. Production of Vaccines in Different Expression Systems
3.4.2.1. Avian Expression Systems
3.4.2.2. Bacterial Expression Systems
3.4.2.3. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
3.4.2.4. Insect Expression Systems
3.4.2.5. Mammalian Expression Systems
3.4.2.6. Plant Expression Systems
3.4.2.7. Yeast Expression Systems
3.4.3. Vaccine Manufacturing Process
3.4.3.1. Upstream Process
3.4.3.2. Downstream Process
3.4.3.3. Formulation and Fill / Finish
3.4.4. Clinical Development and Approval
3.4.5. Vaccine Supply Chain and Logistics
3.5. Vaccine Contract Manufacturing
3.5.1. Need for Outsourcing Vaccine Manufacturing Operations
3.5.2. Commonly Outsourced Operations
3.5.3. Selecting a Contract Manufacturing Partner
3.5.4. Advantages of Outsourcing Manufacturing Operations
3.5.5. Risk Factors and Challenges


4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Vaccine Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size and Geographical Location
4.2.3. Analysis by Geography
4.2.4. Analysis by Type of Service(s) Offered
4.2.5. Analysis by Scale of Operation
4.2.6. Analysis by Type of Expression Systems
4.2.7. Analysis by Type of Vaccines Manufactured


5. COVID-19 VACCINE CONTRACT MANUFACTURERS
5.1. Chapter Overview
5.2. COVID-19 Vaccine CMOs: List of Service Providers
5.2.1. Analysis by Geography
5.2.2. Analysis by Type of Service(s) Offered
5.3. Competitiveness Analysis of COVID-19 Vaccine Contract Manufacturers
5.3.1. Methodology
5.3.2. Assumptions and Key Input Parameters
5.3.3. Competitiveness Analysis: COVID-19 Vaccine Contract Manufacturers based in
5.3.4. Competitiveness Analysis: COVID-19 Vaccine Contract Manufacturers based in
5.3.5. Competitiveness Analysis: COVID-19 Vaccine Contract Manufacturers based in
5.4. Demand and Supply of COVID-19 Vaccines
5.4.1. Analysis by Number of Doses Produced
5.4.2. Analysis by Number of Doses Administered
5.4.3. Uncertainties Around COVID-19 Vaccine Demand


6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Assumptions and Key Input Parameters
6.4. Competitiveness Analysis: Vaccine Contract Manufacturers based in North
6.5. Competitiveness Analysis: Vaccine Contract Manufacturers based in Europe
6.6. Competitiveness Analysis: Vaccine Contract Manufacturers based in Asia-Pacific


7. COMPANY PROFILES: VACCINE CONTRACT MANUFACTURERS
7.1. Chapter Overview
7.2. Albany Molecular Research (AMRI) / OSO Biopharmaceuticals Manufacturing
7.2.1. Company Overview
7.2.2. Financial Performance
7.2.3. Vaccine-related Service Portfolio
7.2.3.1. Fill / Finish Services
7.2.3.2. Regulatory Support and Quality Assurance Services
7.2.4. Vaccine Manufacturing Facility
7.2.5. Recent Developments and Future Outlook
7.3. Catalent
7.3.1. Company Overview
7.3.2. Financial Performance
7.3.3. Vaccine-related Service Portfolio
7.3.3.1. Cell Line Development Services
7.3.3.2. Clinical Manufacturing Services
7.3.3.3. Analytical Services
7.3.3.4. Clinical Supply Services
7.3.3.5. Regulatory Support Services
7.3.4. Vaccine Manufacturing Facility
7.3.5. Recent Developments and Future Outlook
7.4. Charles River Laboratories
7.4.1. Company Overview
7.4.2. Financial Performance
7.4.3. Vaccine-Related Service Portfolio
7.4.3.1. Vaccine Development Services
7.4.3.2. Vaccine Manufacturing Services
7.4.3.3. Avian Vaccine Services
7.4.4. Vaccine Manufacturing Facility
7.4.5. Recent Developments and Future Outlook
7.5. Meridian Life Science (MLS)
7.5.1. Company Overview
7.5.2. Financial Performance
7.5.3. Vaccine-Related Service Portfolio
7.5.3.1. Cell and Virus Banking Services
7.5.3.2. Process development and Scale-up Services
7.5.3.3. Formulation Development and Fill / finish Services
7.5.3.4. Regulatory Support Services
7.5.4. Vaccine Manufacturing Facility
7.5.5. Recent Developments and Future Outlook
7.6. BioReliance (A Unit of Merck)
7.6.1. Company Overview
7.6.2. Financial Performance
7.6.3. Vaccine Related Service Portfolio
7.6.3.1. cGMP Cell and Virus Banking Services
7.6.3.2. Process Development Services
7.6.3.3. Biorepository Services
7.6.3.4. Contract Manufacturing Support Services
7.6.4. Vaccine Manufacturing Facility
7.6.5. Recent Developments and Future Outlook
7.7. Other Key Players
7.7.1. AGC Biologics
7.7.1.1. Company Overview


8. COMPANY PROFILES: VACCINE CONTRACT MANUFACTURERS
8.1. Chapter Overview
8.2. Cobra Biologics
8.2.1. Company Overview
8.2.2. Vaccine-related Service Portfolio
8.2.2.1. Viral Vaccines and Virus-related Services
8.2.2.2. DNA Vaccines and DNA-based Services
8.2.2.3. Other Services
8.2.3. Vaccine Manufacturing Facility
8.2.3.1. Facilities in Europe
8.2.4. Recent Developments and Future Outlook
8.3. Eurogentec
8.3.1. Company Overview
8.3.2. Vaccine-related Service Portfolio
8.3.2.1. Manufacturing Services
8.3.2.2. Analytical and Regulatory Support Services
8.3.2.3. Other Services
8.3.3. Recent Developments and Future Outlook
8.4. IDT Biologika
8.4.1. Company Overview
8.4.2. Vaccine-related Service Portfolio
8.4.2.1. Vaccine Development Services
8.4.2.2. Vaccine Manufacturing Services
8.4.2.3. Fill / Finish Services
8.4.2.4. Labeling and Packaging Services
8.4.2.5. Storage Services
8.4.2.6. Quality Control Services
8.4.3. Vaccine Manufacturing Facility
8.4.3.1. Facility in North America
8.4.3.1.1. Maryland, US
8.4.3.2. Facilities in Europe
8.4.3.2.1. Reims, Germany
8.4.3.2.2. Dessau, Germany
8.4.4. Recent Developments and Future Outlook
8.5. Lonza
8.5.1. Company Overview
8.5.2. Financial Performance
8.5.3. Vaccine-related Service Portfolio
8.5.3.1. Process Development and Optimization Services
8.5.3.2. Commercial Manufacturing Services
8.5.3.3. Fill / Finish Services
8.5.3.4. Other Services
8.5.4. Recent Developments and Future Outlook
8.6. Other Key Players
8.6.1. Eurofins Amatsigroup
8.6.1.1. Company Overview
8.6.2. Boehringer Ingelheim BioXcellence
8.6.2.1. Company Overview


9. COMPANY PROFILES: VACCINE CONTRACT MANUFACTURERS
9.1. Chapter Overview
9.2. GreenPak Biotech
9.2.1. Company Overview
9.2.2. Vaccine-related Service Portfolio
9.3. Hong Kong Institute of Biotechnology
9.3.1. Company Overview
9.3.2. Vaccine-related Service Portfolio
9.3.2.1. Manufacturing Services
9.3.3. Vaccine Manufacturing Facility
9.4. WuXi Biologics
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Vaccine-related Service Portfolio
9.4.3.1. Non-Clinical Services
9.4.3.2. Discovery and Early Diagnostic Testing Services
9.4.3.3. Manufacturing Services
9.4.3.4. Support Services
9.4.3.5. Vaccine Testing Services
9.4.4. Recent Developments and Future Outlook
9.5. Bharat Biotech
9.5.1. Company Overview
9.5.2. Vaccine-related Service Portfolio
9.5.3. Vaccine Manufacturing Facility
9.5.4. Recent Developments and Future Outlook
9.6. Biological E
9.6.1. Company Overview
9.6.2. Vaccine-related Service Portfolio
9.6.3. Vaccine Manufacturing Facility
9.6.4. Recent Developments and Future Outlook
9.7. Other Key Players
9.7.1. Syngene International
9.7.1.1. Company Overview
9.7.2. Wockhardt
9.7.2.1. Company Overview


10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Vaccine Contract Manufacturing: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Therapeutic Area
10.3.4. Analysis by Type of Vaccines
10.3.5. Most Active Players: Analysis by Number of Partnerships
10.3.6. Regional Analysis
10.3.6.1. Intercontinental and Intracontinental Agreements


11. RECENT EXPANSIONS
11.1. Chapter Overview
11.2. Vaccine Contract Manufacturing Market: Recent Expansions
11.2.1. Analysis by Year of Expansion
11.2.2. Analysis by Purpose of Expansion
11.2.3. Analysis by Scale of Operation and Purpose of Expansion
11.2.4. Analysis by Company Size and Location of Headquarters
11.2.5. Analysis by Purpose of Expansion and Location of Facility
11.2.6. Analysis by Type of Service(s) Offered
11.2.7. Analysis by Purpose of Expansion and Type of Service(s) Offered
11.2.8. Most Active Players: Analysis by Number of Expansions
11.2.9. Analysis by Geography


12. MERGERS AND ACQUISITIONS
12.1. Chapter Overview
12.2. Merger and Acquisition Models
12.3. Vaccine Contract Manufacturing: Mergers and Acquisitions
12.3.1. Analysis by Year of Acquisition
12.3.2. Analysis by Geography
12.3.3. Intercontinental and Intracontinental Deals
12.4. Analysis by Key Value Drivers
12.4.1. Mergers and Acquisitions: Analysis by Key Value Drivers
12.5. Valuation Analysis: Acquisition Deal Multiples
12.5.1. Prominent Acquirers: Analysis by Number of Acquisitions


13. CAPACITY ANALYSIS
13.1. Chapter Overview
13.2. Assumptions and Methodology
13.3. Vaccine Contract Manufacturing Market: Global Production Capacity (in Million
13.3.1. Analysis by Company Size
13.3.2. Analysis by Type of Expression System Used
13.3.3. Analysis by Scale of Operation
13.3.4. Analysis by Region
13.4. Conclusion


14. DEMAND ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Global Clinical Demand for Vaccines
14.3.1. Analysis by Type of Vaccine
14.3.2. Analysis by Indication
14.3.3. Analysis by Geography
14.4. Global Commercial Demand for Vaccines
14.4.1. Analysis by Type of Vaccine
14.4.2. Analysis by Geography
14.5. Demand and Supply Analysis
14.5.1. Demand and Supply Analysis (Scenario 1)
14.5.2. Demand and Supply Analysis (Scenario 2)
14.5.3. Demand and Supply Analysis (Scenario 3)


15. MARKET FORECAST
15.1. Chapter Overview
15.2. Forecast Methodology and Key Assumptions
15.3. Overall Vaccine Contract Manufacturing Market, 2021-2030
15.4. Vaccine Contract Manufacturing Market, 2021-2030: Distribution by Type of
15.5. Vaccine Contract Manufacturing Market, 2021-2030: Distribution by Scale of
15.6. Vaccine Contract Manufacturing Market, 2021-2030: Distribution by Company
15.7. Vaccine Contract Manufacturing Market, 2021-2030: Distribution by Geography
15.7.1. Vaccine Contract Manufacturing Market in North America, 2021-2030
15.7.1.1. Vaccine Contract Manufacturing in the US, 2021-2030
15.7.1.2. Vaccine Contract Manufacturing in Rest of North America, 2021-2030
15.7.1.3. Vaccine Contract Manufacturing Market in North America for Mammalian Cell-
15.7.1.4. Vaccine Contract Manufacturing Market in North America for Microbial Cell-
15.7.1.5. Vaccine Contract Manufacturing Market in North America for Other Expression
15.7.1.6. Vaccine Contract Manufacturing Market in North America for Preclinical /
15.7.1.7. Vaccine Contract Manufacturing Market in North America for Commercial Scale
15.7.1.8. Vaccine Contract Manufacturing Market in North America for Small
15.7.1.9. Vaccine Contract Manufacturing Market in North America for Mid-sized
15.7.1.10. Vaccine Contract Manufacturing Market in North America for Large / Very Large
15.7.2. Vaccine Contract Manufacturing in Europe, 2021-2030
15.7.2.1. Vaccine Contract Manufacturing in Italy, 2021-2030
15.7.2.2. Vaccine Contract Manufacturing in Germany, 2021-2030
15.7.2.3. Vaccine Contract Manufacturing in France, 2021-2030
15.7.2.4. Vaccine Contract Manufacturing in Spain, 2021-2030
15.7.2.5. Vaccine Contract Manufacturing in the UK, 2021-2030
15.7.2.6. Vaccine Contract Manufacturing in Rest of Europe, 2021-2030
15.7.2.7. Vaccine Contract Manufacturing Market in Europe for Mammalian Cell-based
15.7.2.8. Vaccine Contract Manufacturing Market in Europe for Microbial Cell-based
15.7.2.9. Vaccine Contract Manufacturing Market in Europe for Other Expression System-
15.7.2.10. Vaccine Contract Manufacturing Market in Europe for Preclinical / Clinical Scale
15.7.2.11. Vaccine Contract Manufacturing Market in Europe for Commercial Scale
15.7.2.12. Vaccine Contract Manufacturing Market in Europe for Small Companies, 2030
15.7.2.13. Vaccine Contract Manufacturing Market in Europe for Mid-sized Companies,
15.7.2.14. Vaccine Contract Manufacturing Market in Europe for Large / Very Large
15.7.3. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World,
15.7.3.1. Vaccine Contract Manufacturing Market in China, 2021-2030
15.7.3.2. Vaccine Contract Manufacturing Market in India, 2021-2030
15.7.3.3. Vaccine Contract Manufacturing Market in Japan, 2021-2030
15.7.3.4. Vaccine Contract Manufacturing Market in Rest of Asia-Pacific and Other
15.7.3.5. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for
15.7.3.6. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for
15.7.3.7. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for
15.7.3.8. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for
15.7.3.9. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for
15.7.3.10. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for
15.7.3.11. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for
15.7.3.12. Vaccine Contract Manufacturing Market in Asia-Pacific and Rest of the World for


16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of Swot Factors


17. FUTURE GROWTH OPPORTUNITIES
17.1. Chapter Overview
17.2. Growing Manufacturing demand in the Wake of COVID-19
17.3. Advances in Technologies to Drive Growth in the Vaccine Manufacturing Industry
17.4. Shift to Single-Use Systems and Components
17.5. The Advent of Virus-like Particles (VLPs)
17.6. Growing Investments in Existing Infrastructure
17.7. Evolving Client / Sponsor and CMO / CDMO Relationships
17.8. Business Acquisition and Consolidation Activity


18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Batavia Biosciences
18.2.1. Company Snapshot
18.2.1.1. Interview Transcript: Menzo Havenga, President and Chief Executive Officer
18.3. Polymun Scientific
18.3.1. Company Snapshot
18.3.1.1. Interview Transcript: Dietmar Katinger, Chief Executive Officer
18.4. Goodwin Biotechnology
18.4.1. Company Snapshot
18.4.1.1. Interview Transcript: David C Cunningham, Director Corporate Development (Q3
18.5. Statens Serum Institut
18.5.1. Company Snapshot
18.5.1.1. Interview Transcript: Ingrid Kromann, Ex-Director – Vaccine Development
18.6. Novasep Synthesis
18.6.1. Company Snapshot
18.6.1.1. Interview Transcript: Kevin Daley, Director Pharmaceuticals (Q3 2019)
18.7. Richer-Helm BioLogics
18.7.1. Company Snapshot
18.7.1.1. Interview Transcript: Thilo Kamphausen, Director Business Development
18.8. Wacker Biotech
18.8.1. Company Snapshot
18.8.1.1. Interview Transcript: Sebastian Schuck, Head of Business Development (Q3 2019)
18.9. ProBioGen
18.9.1. Company Snapshot
18.9.1.1. Interview Transcript: Oliver Schub, Senior Business Development Manager (Q3 2019)


19. CONCLUDING REMARKS20. APPENDIX 1: TABULATED DATA21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Companies Mentioned

  • 3P Biopharmaceuticals
  • ABEC
  • Abenza
  • Acambis
  • Accinov (acquired by ABL)
  • Accugenix (acquired by Charles River Laboratories)
  • Actavis
  • AdaptVac
  • Adimmune
  • Advanced BioScience Laboratories (ABL)
  • Advaxis
  • Advent
  • Aeras
  • Aeras's Biopharmaceutical Development Center (BDC)
  • AGC Biologics
  • AJ Biologics
  • Ajinomoto Bio-Pharma Services
  • Akers Biosciences
  • Akorn India (acquired by Biological E)
  • Akshaya Bio
  • Albany Molecular Research
  • Alexion Pharmaceuticals
  • Algonomics
  • Altaris Capital Partners
  • Altimmune
  • Amatsigroup
  • AmbioPharm
  • AmpTec (acquired by Merck)
  • AnaSpec
  • Aptuit
  • Arabio
  • Aragen Bioscience
  • Arcturus Therapeutics
  • Argonaut Manufacturing Services
  • Aspen Pharmacare
  • Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)
  • AstraZeneca
  • Aventis Pasteur
  • Avid Bioservices
  • Bachem
  • Batavia Biosciences
  • Battelle
  • Bavarian Nordic
  • Baxter BioPharma Solutions
  • Bayer
  • Baylor College of Medicine
  • Baylor Institute for Immunology Research (BIIR)
  • BD Biosciences
  • Bharat Biotech
  • Bharat Serums and Vaccine
  • Bill & Melinda Gates Foundation
  • Bilthoven Biologicals
  • Binex
  • BioCell
  • Biocon
  • BioConnections
  • Biodextris
  • Bio-Ess Laboratories
  • Biofabri
  • Biofarma
  • Biogen
  • Bioline (acquired by Meridian Life Sciences)
  • Biological E
  • BioMARC
  • Biomay
  • Biomed Research International
  • Biomedical Advanced Research and Development Authority (BARDA)
  • BioMotiv
  • BiondVax Pharmaceuticals
  • BioNTech
  • BioReliance
  • BioTechLogic
  • BioTechnique
  • Biotechnology and Biological Sciences Research Council
  • Biotechnology Development for Industry
  • Biovac
  • BioVaxys Technology
  • Biovest International
  • BirgiMefar 
  • Blue Water Vaccines
  • Boehringer Ingelheim BioXcellence
  • Boston Children’s Hospital
  • Brammer Bio (acquired by Thermo Fisher Scientific)
  • BravoVax
  • Bristol-Myers Squibb
  • Bryllan
  • Burrard Pharmaceuticals
  • CALIXAR
  • Canadian Animal Health Institute (CAHI)
  • Cangene
  • CARBOGEN AMCIS
  • Catalent
  • Celsis International (acquired by Charles River Laboratories)
  • Centers for Disease Control and Prevention (CDC)
  • Century Pharmaceuticals
  • CEPiA
  • Cetus 
  • CEVEC
  • Changchun BCHT Biotechnology
  • Charles River Laboratories
  • Chimera Biotec
  • China Agricultural University
  • China National Biotec Group (CNBG)
  • Chinese Center for Disease Control and Prevention
  • Chinese University of Hong Kong
  • Chiron Behring Vaccines
  • Coalition for Epidemic Preparedness Innovations (CEPI)
  • Cobra Biologics
  • Cognate BioServices
  • Commonwealth Serum Laboratories (CSL)
  • Cook Pharmica
  • CordenPharma
  • Crucell 
  • CureVac
  • Cytovance Biologics
  • Daiichi Sankyo
  • Dalton Pharma Services
  • de Duve Institute
  • Delpharm
  • Deltamune
  • Department of Defense
  • Dermapharm
  • Disposable Lab
  • Dr. Reddy's Laboratories
  • Dyadic International
  • Dynavax Technologies
  • EGYVAC
  • EirGenix
  • Emergent BioSolutions
  • Endo International
  • Engineering and Physical Sciences Research Council
  • Epygen Biotech
  • ERC Belgium
  • EuBiologics
  • Eurogentec
  • European Commission
  • European Medicines Agency
  • ExpreS2ion Biotechnologies
  • Exxell BIO
  • Fareva
  • Federation of Indian Chambers of Commerce and Industry (FICCI)
  • Florida Biologix
  • FluGen
  • Frederick National Laboratory
  • French National Agency for Research on AIDS and Viral Hepatitis
  • Friedrich-Loeffler-Institut
  • FUJIFILM Diosynth Biotechnologies
  • Gallant Custom Laboratories
  • Gamma Vaccines
  • GAVI Alliance 
  • GC Cell
  • GC Pharma
  • Genentech
  • Geneos Therapeutics
  • GENEWIZ
  • GenIbet Biopharmaceuticals
  • Genopis (acquired by Wacker Biotech)
  • Genzyme Polyclonals
  • GeoVax
  • GlaxoSmithKline
  • GNH India 
  • Goodwin Biotechnology
  • Grand River Aseptic Manufacturing
  • GreenPak Biotech
  • GreenSignal Bio Pharma
  • Griffith University
  • Grifols
  • GSAL
  • GTP Technology
  • Guangxi Veterinary Research Institute
  • Guangzhou Air force Hospital
  • Haffkine Institute
  • HALIX
  • Harbin Veterinary Research Institute (HVRI)
  • Health Biotech
  • Heat Biologics
  • Hennepin Healthcare Research Institute (HHRI)
  • Hetero Biopharma
  • HLL Biotech
  • Hong Kong Institute of Biotechnology
  • IDT Biologika
  • IMAXIO
  • ImevaX
  • Immune Design 
  • Immune Targeting Systems
  • Immunex
  • ImmunityBio
  • Immunobiological Technology Institute (Bio-Manguinhos)
  • ImmunoSite Technologies
  • ImVisioN Therapeutics
  • Index Ventures
  • Indian Council of Medical Research
  • Indian Immunologicals
  • Infectious Disease Research Institute
  • Innovate UK
  • INOVIO
  • INSERM-ANRS
  • Instituto Butantan
  • Insud Pharma
  • Intas
  • Integrity Bio
  • International AIDS Vaccine Initiative (IAVI)
  • International Medica Foundation
  • International Society for Pharmaceutical Engineering
  • International Vaccine Institute
  • Interros
  • Intervacc
  • Inviragen (acquired by Takeda Pharmaceutical)
  • Irvine Pharmaceutical Services 
  • Israel Institute for Biological Research (IIBR)
  • Janssen Pharmaceuticals
  • Janssen Vaccines & Prevention
  • Jenner Institute
  • JHL Biotech
  • JHP Pharmaceuticals
  • Johnson & Johnson
  • JSR
  • Jubilant HollisterStier
  • KABS Pharmaceutical Services
  • Kalon Biotherapeutics (acquired by FUJIFILM Diosynth Biotechnologies)
  • Kaneka
  • Karolinska Institutet
  • KBI Biopharma
  • Keensight Capital
  • Kemwell Biopharma
  • Kitasato Daiichi Sankyo Vaccine
  • KP Pharmaceutical Technology
  • KU Leuven
  • Liaoning Chengda Biological
  • LigoCyte Pharmaceuticals (acquired by Takeda Pharmaceutical)
  • Lonza
  • LuinaBio
  • Liminal Biosciences
  • Magellan BioScience Group
  • Massachusetts General Hospital
  • MassBiologics
  • Medicago
  • Medicines and Healthcare products Regulatory Agency
  • Merck
  • Meridian Life Science
  • MilliporeSigma
  • Minhai Biotechnology
  • Ministry of Health & Welfare, South Korea
  • Minneapolis Medical Research Foundation (MMRF)
  • Mitsubishi Gas Chemical
  • Mitsubishi Tanabe Pharma
  • Moderna Therapeutics
  • MSD France
  • Mymetics
  • Najít Technologies
  • Nanotherapeutics
  • National Avian Influenza Reference Laboratory
  • National Cancer Institute
  • National Health Research Institute    
  • National Heart, Lung, and Blood Institute
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • National Institutes of Health (NIH)
  • NewLink Genetics
  • Nitto Avecia Pharma Services
  • Norwegian Institute of Public Health
  • Nouscom
  • Novartis
  • Novasep
  • Novavax
  • OctoPlus
  • Ocugen
  • Ohio State Innovation Foundation (OSIF)
  • Okairos
  • Ology Bioservices
  • Oncotest
  • Oragenics
  • Organisation for Economic Co-operation and Development (OECD)
  • OSO BioPharmaceuticals Manufacturing (acquired by AMRI)
  • Ottawa Hospital Research Institute (OHRI)
  • Oxford Biomedica
  • Oxford University
  • Pacific GMP
  • Panacea Biotec
  • Panacea Pharmaceuticals
  • Paragon Bioservices
  • PATH
  • Patheon
  • PaxVax
  • Petrovax
  • Pfenex
  • Pfizer
  • Pfizer CentreOne
  • PharmaPak (acquired by Catalent Pharma Solutions)
  • PharmaSynth
  • Phlow
  • Pierre Fabre
  • Piramal Pharma Solutions
  • Polymun Scientific
  • Porton Biopharma
  • Praha Vaccines (acquired by Novavax)
  • Precisa Medicamentos
  • Premas Biotech
  • Prime European Therapeuticals (acquired by Livia)
  • ProBioGen
  • Profectus BioSciences
  • Prometic Life Sciences
  • Protagen
  • PX’Therapeutics
  • QuiaPEG Pharmaceuticals
  • RAFAGEN
  • Recipharm
  • Refana
  • Reliance Life Sciences
  • Rentschler Biopharma
  • Richter-Helm BioLogics 
  • RIEMSER Pharma (acquired by Esteve)
  • Rommelag CMO
  • ROVI Pharma Industrial Services
  • Russian Direct Investment Fund (RDIF)
  • SAFC
  • Saiba
  • Sanofi
  • Sanofi Active Ingredient Solutions
  • Sanofi Pasteur
  • Sanofi-Aventis
  • Sartorius Stedim Biotech
  • Scancell
  • Seikagaku
  • Seoul National University Hospital
  • Seqirus
  • Serum Institute of India
  • Shandong Zhaoxin Bio-tech
  • Shanghai Laboratory Animal Center
  • ShangPharma Innovation
  • Shasun Pharmaceuticals 
  • Shenzhen Kangtai Biological Products
  • SialoCarb
  • Sichuan Agricultural University
  • Siegfried
  • Sigma-Aldrich
  • Singota Solutions
  • SK Bioscience
  • SK Chemicals
  • Soligenix
  • South African Tuberculosis Vaccine Initiative (SATVI)
  • South China Agricultural University
  • Spicona
  • SpyBiotech
  • Stabilitech Biopharma
  • State Secretariat for Education, Research and Innovation
  • Statens Serum Institut
  • Stellar Biotechnologies
  • Sumagen
  • Swissfillon
  • Symbiosis Pharmaceutical Services
  • SynCo Bio Partners
  • Syngene
  • Synthelis
  • Takara Bio
  • Takeda Pharmaceuticals
  • Temasek Life Sciences Ventures
  • The Cell and Gene Therapy Catapult
  • The Coalition for Epidemic Preparedness Innovations (CEPI)
  • The Friedrich-Loeffler-Institut
  • The Hong Kong Jockey Club Charities Trust
  • The Wistar Institute
  • Themis Medicare
  • TheraVectys
  • Thermo Fisher Scientific
  • Thomas Jefferson University
  • Tianjin CanSino Biotechnology
  • Tonix Pharmaceuticals
  • Transgene
  • Translate Bio
  • Unitech Pharmaceuticals 
  • United Nations International Children's Emergency Fund (UNICEF)
  • United States Army Medical Research Institute of Infectious Diseases
  • Univercells
  • Universitätsklinikum Tübingen
  • University of Copenhagen
  • University of Iowa Pharmaceuticals
  • University of Maryland
  • University of Oxford
  • University of Pennsylvania
  • University of Tokyo
  • University of Wisconsin - Madison
  • Upperton Pharma Solutions
  • Vaccibody
  • Vaccine and Infectious Disease Organization–International Vaccine Centre (VIDO-        InterVac)
  • Vaccines Manufacturing and Innovation Centre (VMIC)
  • Vaccitech
  • VACSERA
  • Valerius Biopharma
  • Valneva
  • Vaxart
  • Vaxess Technologies
  • Vetter Pharma
  • VGXI
  • Vibalogics
  • VIRCHOW BIOTECH
  • Vivalis
  • Vipassana Research Institute (VRI)
  • Vybion
  • Wacker Biotech
  • Waisman Biomanufacturing
  • Walter Reed Army Institute of Research
  • Washington University School of Medicine
  • Wellcome Trust
  • WIL Research
  • Wockhardt
  • World Trade Organization
  • WuXi AppTec
  • WuXi Biologics
  • Wuxi Fortune Pharmaceutical
  • Wuxi Griffin
  • Zoetis 
  • Zydus Cadila

Methodology

 

 

Loading
LOADING...